Simelglutide Adds New Indication

  Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), which has been approved for the treatment of type 2 diabetes mellitus and obesity in several countries and regions around the world.

Indications that have been approved in China include:

1. Type 2 diabetes: Simeglutide is approved as Novotel in China for the treatment of type 2 diabetes.

2. Obesity: NovoTech (simepaglutide injection) is approved in China for long-term weight management in overweight and obese patients

3. Indications for weight loss: Simeglutide Injection is approved for weight loss in China for adult patients with an initial BMI greater than or equal to 30 kg/m2.

4. Oral form: Novosin® (simethicone tablets) was approved in China, marking the oral era of the GLP-1RA class of drugs for the treatment of type 2 diabetes in adults

   In March 2024, the FDA approved simethicone for reducing the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and who are obese or overweight. Recently, the indication has also been approved in the UK and EU, further expanding its market reach.

  Currently, Novo Nordisk has conducted more than 100 clinical trials for simepaglutide. Some of these indications are related to complications arising from diabetes and obesity, including chronic kidney disease (CKD), heart failure, non-alcoholic steatohepatitis (NASH/MASH), and cardiovascular disease, in addition to cardiovascular disease risk.

 In addition, Simeglutide is expanding indications for Alzheimer‘s disease, ischemic stroke, Parkinson‘s disease, polycystic ovary syndrome and peripheral arterial disease, among many other promising disease areas in the market.